Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With<i>RAS</i>Wild-Type Advanced Colorectal Cancer

Jenny F. Seligmann(University of Leeds), Michel Seymour(University of Leeds), Sabine Tejpar(KU Leuven), Faye Elliott(University of Leeds), Philip Quirke(University of Leeds), Bart Jacobs, Jennifer H. Barrett(University of Leeds), Gemma Hemmings(University of Leeds), Sarah Brown(University of Leeds), Susan D. Richman(University of Leeds)
JAMA Oncology
February 12, 2016
10.1001/jamaoncol.2015.6065
Cited by 115

Related Papers

The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial
|The Lancet|2009|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k
Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial
|The Lancet|2009|1.1k